Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

42 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05319886 2022-05-20

AP

Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04325763 2022-03-31

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Phase 3 Unknown

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05218759 2022-02-01

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Phase NA Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04797806 2021-03-15

SAINT

Phase 3 Unknown

206 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04273815 2020-07-08

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03624309 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04181372 2019-11-29

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03910127 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03769805 2019-10-22

CSOAIMTOAN

Phase NA Unknown

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04124731 2019-10-11

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

98 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

20 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03728374 2018-11-02

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03672136 2018-09-14

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03654027 2018-08-31

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

110 enrolled